- Details
- Sam Chang hosts a conversation with Vignesh Packiam to discuss the emerging role of intravesical gemcitabine and docetaxel (gem/doce) for treating non-muscle invasive bladder cancer (NMIBC), spotlighting Dr. Packiam's recent publication in Urologic Oncology. The study, a retrospective review focusing on AUA intermediate-risk NMIBC patients, demonstrates the regimen's efficacy and tolerability. It...
|
- Details
- Sam Chang leads a discussion with Ashish Kamat and Matt Galsky on their co-authored article, focusing on new trial parameters for urothelial carcinoma. This collaboration, involving SITC, IBCG, FDA stakeholders, and patient advocates, responds to the urgent need for detailed clinical trial guidelines due to the dynamic landscape of bladder cancer treatment. The dialogue highlights the transition t...
|
- Details
- Sam Chang converses with Ashish Kamat about a study exploring age's influence on treatment outcomes for non-muscle invasive bladder cancer patients. Despite common beliefs that older patients may not respond as well to intravesical therapy, their research challenges this notion, suggesting age should not deter from appropriate treatment. Utilizing a robust dataset, they found no significant differ...
|
- Details
- Kyle Richards delves into the subject of environmental factors influencing bladder cancer, particularly focusing on the potential carcinogenic effects of Agent Orange on non-muscle invasive bladder cancer. Dr. Richards highlights the recognition of Agent Orange by the VA as a linked carcinogen to bladder cancer, allowing veterans exposure benefits. Through an observational retrospective study invo...
|
- Details
- Sam Chang is joined by James (Jed) Ferguson to explore disparities in the treatment of muscle-invasive bladder cancer. Dr. Ferguson's team delved into the National Cancer Database, revealing that a significant percentage of patients do not receive aggressive treatments post-TURBT, with factors such as age, comorbidity, race, insurance status, and treatment facility type playing crucial roles in th...
|
- Details
- Sam Chang engages with Arlene Siefker-Radtke to explore the transformative impact of erdafitinib in treating advanced and metastatic urothelial cancer. Dr. Siefker-Radtke illuminates the targeted approach of erdafitinib, emphasizing its efficacy in hitting specific genetic alterations, particularly FGFR3/2 mutations, prevalent in 15-20% of metastatic bladder tumors. Highlighting the drug's journey...
|
- Details
- Ashish Kamat converses with Akshay Sood about the challenging diagnosis and management of non-metastatic plasmacytoid bladder cancer. Dr. Sood elaborates on his comprehensive study published in the Journal of Urology. He highlights the rarity and lethal nature of the plasmacytoid variant, which represents approximately 1% of muscle-invasive bladder cancers. Through a retrospective analysis of 56 p...
|
- Details
- Sam Chang converses with Neal Shore about the KEYNOTE-676 trial, focusing on combining pembrolizumab with BCG for high-risk NMIBC patients previously treated with BCG. This study aims to explore the potential synergy between two immunotherapeutic agents, leveraging pembrolizumab's success in MIBC to improve outcomes in NMIBC. With enrollment progressing well, the trial signals a collaborative futu...
|
- Details
- Sam Chang engages with Roger Li to delve into the TAR-210 study, focusing on bladder-based intravesical therapy targeting FGFR3 in non-muscle invasive bladder cancer (NMIBC) patients. Dr. Li shares insights from the multi-site international study, highlighting the efficacy of Erdafitinib, particularly in patients with FGFR alterations. Despite the challenges with oral Erdafitinib's toxicity, the i...
|
- Details
- Sam Chang and Roger Li delve into a study examining genetic profiles in non-muscle invasive bladder cancer and adjacent benign bladder tissue. Conducted on a cohort of nine patients, the study leveraged whole exome sequencing to explore mutations in both cancerous and non-cancerous tissue samples, uncovering a significant mutation overlap yet a lower mutation count in benign tissues. This investig...
|
